


GRPR antagonist-2

Cat. No.:	HY-115975
Molecular Formula:	C ₂₈ H ₃₂ F ₃ N ₅ O ₄
Molecular Weight:	559.58
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	GRPR antagonist-2 is a potent gastrin releasing peptide receptor (GRPR) antagonist, having the cytotoxicity against certain cancer cells (IC ₅₀ of 0.77 and 2.5 μM in HGC-27 and Pan02 cells, respectively). Anticancer activity ^[1] .								
IC₅₀ & Target	IC ₅₀ : 0.77 μM (GRPR) in HGC-27, 2.5 μM (GRPR) in Pan02 ^[1]								
In Vitro	<p>GRPR antagonist-2 (compound 6e) (0.032-100 μM; 48 hours) has the cytotoxicity against certain cancer cells, also reduces PC3, Pan02, HGC-27, and HepG2 cell viability combined with HDAC inhibitor (1 μM)^[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <p>Cell Proliferation Assay</p> <table border="1"> <tr> <td>Cell Line:</td> <td>PC3, HepG2, HGC-27, Pan02, and HK2 cells^[1]</td> </tr> <tr> <td>Concentration:</td> <td>0.032-100 μM</td> </tr> <tr> <td>Incubation Time:</td> <td>48 hours</td> </tr> <tr> <td>Result:</td> <td>Showed the cytotoxicity against these cancer cells, also reduced PC3, Pan02, HGC-27, and HepG2 cell viability combined with HDAC inhibitor (1 μM).</td> </tr> </table>	Cell Line:	PC3, HepG2, HGC-27, Pan02, and HK2 cells ^[1]	Concentration:	0.032-100 μM	Incubation Time:	48 hours	Result:	Showed the cytotoxicity against these cancer cells, also reduced PC3, Pan02, HGC-27, and HepG2 cell viability combined with HDAC inhibitor (1 μM).
Cell Line:	PC3, HepG2, HGC-27, Pan02, and HK2 cells ^[1]								
Concentration:	0.032-100 μM								
Incubation Time:	48 hours								
Result:	Showed the cytotoxicity against these cancer cells, also reduced PC3, Pan02, HGC-27, and HepG2 cell viability combined with HDAC inhibitor (1 μM).								

REFERENCES

[1]. Yu, Mj., et al. Structure–activity relationship studies on Pd176252 derivatives leading to discovery of novel GRP receptor antagonist with potent anticancer activity. *Med Chem Res* 30, 2069–2089 (2021).

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA